68Ga-NOTA-3PTATE-RGD
- Generic Name
- 68Ga-NOTA-3PTATE-RGD
A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors
Early Phase 1
Recruiting
- Conditions
- Iodine-resistant Thyroid CancerMeningiomaNETs
- Interventions
- Drug: 18-FDG
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06632860
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT02817945
- Locations
- 🇨🇳
Peking Union Medical College Hospitall, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath